New data show Shionogi's COVID-19 vaccine S-268019 matches Comirnaty
Japanese pharma major Shionogi (TYO: 4507) today announced the interim report of a Phase II/III additional dose clinical trial of S-268019, a preventive vaccine for COVID-19.
This adds to Shionogi’s coronavirus pipeline, which includes S-217622, an orally administered antiviral drug for COVID-19, on which the company last month reported Phase IIa results and submission for regulatory review.
The primary endpoint of the Phase II/III additional clinical trial is the geometric mean antibody titer (GMT) of neutralizing antibody titer and seroresponse rate of SARS-CoV-2 neutralizing antibody titer on the 29th day (28 days after inoculation). The non-inferiority of immunogenicity compared to Comirnaty intramuscular injection when S-268019 or Comirnaty was vaccinated for the third time in 206 adults, six months or more after receiving two inoculations of Comirnaty, as well as safety were evaluated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze